Scott Shepardson
About Scott Shepardson
Scott Shepardson is the District Business Manager for Hematology/Oncology in Hartford at Bristol-Myers Squibb, with over 20 years of experience in the pharmaceutical industry.
Title and Role at Bristol-Myers Squibb
Scott Shepardson currently holds the role of District Business Manager Hematology/Oncology Hartford at Bristol-Myers Squibb. He transitioned to this role in 2020 after serving as District Business Manager for the Boston district from 2008 to 2020, marking a significant shift in his geographic responsibilities while maintaining his focus on hematology and oncology.
Education Background in Business Administration
Scott Shepardson completed his undergraduate education at Eastern Nazarene College, where he earned a Bachelor's degree in Business Administration and Management, General. He studied at the college from 1985 to 1990, giving him a solid foundation in business principles that he has applied throughout his career in the pharmaceutical industry.
Experience in the Pharmaceutical Industry
With over 20 years of experience in the pharmaceutical industry, Scott Shepardson has cultivated a deep expertise in hematology and oncology. His extensive career has provided him with the knowledge and skills necessary to manage business operations and sales strategies effectively within these specialized medical fields.
Career Transition and Responsibilities
In 2020, Scott Shepardson transitioned from his role managing Bristol-Myers Squibb's Boston district to the Hartford district. This move underscores his adaptability and leadership within the company, as he continues to drive business success and oversee the strategic direction for hematology and oncology sales operations in a new region.
Mentorship and Team Development
Scott Shepardson is actively involved in mentoring and developing new talent within Bristol-Myers Squibb. His commitment to mentorship has helped cultivate a culture of growth and learning, ensuring that new team members are well-prepared to contribute to the company's success in the competitive fields of hematology and oncology.